MedTrace Logo

A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

NCT02792803 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-07-26

No results posted yet for this study

Summary

The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with primary open angle glaucoma. The study will also aim to prove the tolerability of Xalatan in terms of ocular hyperemia will be equivalent to its generic counterparts.

Conditions

Interventions

DRUG

Xalatan

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

DRUG

Apo-Latanoprost

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

DRUG

Co-Latanoprost

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Dr. David Yan

    lead OTHER

Principal Investigators

  • David B Yan, M.D., F.R.C.S. (C) · Ophthalmic Diagnostic Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-04-30
Completion
2017-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02792803 on ClinicalTrials.gov